NEW SELECTIVE A2A AGONISTS AND A3 ANTAGONISTS FOR HUMAN ADENOSINE RECEPTORS.
SYNTHESIS, BIOLOGICAL ACTIVITY AND MOLECULAR DOKING STUDIES

Anna Rodríguez,a Angel Guerrero,*a Hugo Gutierrez-de-Terán,b David Rodríguez,c José Brea,d María I. Loza,d Gloria Rosell,e M. Pilar Bosch,*a

aDept. of Biological Chemistry and Molecular Modelling, IQAC (C.S.I.C.), 08034-Barcelona, Spain.
bDept. of Cell and Molecular Biology, Uppsala University, Biomedical Center, Box 596, SE-751 24 Uppsala, Sweden.
cDept. of Biochemistry and Biophysics and Center for Biomembrane Research, Stockholm University, SE-106 91 Stockholm, Sweden.
dBiofarma research group. Center of Research in Molecular Medicine and Chronic Diseases (CIMUS), 15782-Santiago de Compostela, Spain.
eDept. of Pharmacology and Medicinal Chemistry (Unity Associated to CSIC), Fac. Pharmacy, University of Barcelona, Av. Diagonal, s/n, 08028-Barcelona, Spain.

*Corresponding authors. Tel.: +34 934006120 (A.G.), tel.: +34 934006171 (P.B.); fax: +34 932045904. E-mail: angel.guerrero@iqac.csic.es (A. Guerrero);
pilar.bosch@iqac.csic.es (M. Pilar Bosch)
Experimental Section

General

NMR spectra were recorded at 300, 400, or 500 MHz for $^1$H and 75 or 100 MHz for $^{13}$C on a Varian Unity 300, Varian Mercury 400, or Varian Inova 500 spectrometer. The values are expressed in $\delta$ relative to the CHCl$_3$ present in the solvent ($\delta$ 7.24 ppm for $^1$H and $\delta$ 77.0 ppm for $^{13}$C). Alternatively, when CD$_3$OD was used, the values are expressed relative to CD$_3$OH signal at 3.31 ppm for $^1$H and 49.0 ppm for $^{13}$C. Coupling constants (J) are in Hz. High resolution mass spectra (HRMS) were run on a UPLC Acquity apparatus (Waters Corporation, Milford, MA, USA) coupled to a mass spectrometer LCT Premier XE (Waters) with a TOF analyzer using a 1.7 $\mu$m C18 (2.1 x 50 mm) column. Semipreparative HPLC was run on a Waters Alliance 2695 apparatus with a 996 UV photodiode array detector (Waters) using a Gemini 110 Å, 5 $\mu$m C-18 (250 x 10 mm) column (Phenomenex, Torrance, USA) connected to a Waters Fraction Collector III. For analytical HPLC, a Gemini 5520-65 110 Å, 5 $\mu$m C-18 (250 x 4.6 mm) (Phenomenex, Torrance, USA) column was used. All final compounds were checked for purity by analytical HPLC analysis and resulted to be >98% pure.

All reactions were carried out under inert atmosphere. All reagents were purchased from Sigma-Aldrich (Spain) and were used without further purification. THF was distilled from sodium-benzophenone ketyl, MeOH and DMF were distilled from CaH$_2$, i-Pr$_2$NET was distilled from KOH, and DBU and DMSO were distilled from CaH$_2$. For flash column chromatography, silica gel (35-70 $\mu$m) (SDS) was used.

General procedure for preparation of compounds 1-7.

2-[1-($R$)-Methyl-2-(4-methoxyphenyl)ethylamino]-5’-(2-ethyl-2H-tetrazol-5-yl)adenosine (($R$)-6). A mixture of ($R$)-1-(4-methoxyphenyl)propan-2-amine (12f) (14 mg, 0.089 mmol), compound 8 (15 mg, 0.041 mmol), anhydrous DMSO (38 $\mu$L) and i-Pr$_2$NET (0.11 mL, 0.639 mmol) was heated under Ar at 145 ºC for 23 h. The mixture was cooled to room temperature, diluted with AcOEt (5 mL) and the volatile material was removed under vacuum. Then, AcOEt (5 mL) was added and the organic phase was washed with NaCl sat. soln. (4 x 10 mL). After drying (MgSO$_4$) and filtered, the solvent was evaporated. The crude was purified by flash column chromatography eluting with AcOEt:MeOH (95:5) followed by chromatography on a reverse phase C-18 Isolute column eluting with H$_2$O:MeCN:AcOH mixture (75:25:0.1). After evaporation of the solvent and lyophilization, the residue was finally purified by semipreparative HPLC using mixtures of MeOH:H$_2$O (50-95% MeOH) to afford compound ($R$)-6 (6 mg, 30%).

$^1$H NMR (500 MHz, MeOD): $\delta$ 8.10 (s, 1H, NCH$_3$), 7.17 (d, J= 8.7 Hz, 2H, C$_6$H$_4$), 6.82 (d, J = 9 Hz, 2H, C$_6$H$_4$), 6.13 (d, J = 4.5 Hz, 1H, CHO), 5.32 (d, J = 4.5 Hz, 1H, NCCCHO), 4.74 (m, 1H, CHO), 4.71 (m, 1H, CHO), 4.69 (q, 2H, J = 7.5 Hz, CH$_2$CH$_3$), 4.23 (m, 1H, CH$_3$), 3.65 (s, 3H, OCH$_3$), 2.89 (dd, J = 13.5 Hz, J’ = 5.7 Hz, 1H, CH$_2$), 2.64 (dd, J = 13.2 Hz, J’ = 7.2 Hz, 1H, CH$_2$), 1.60 (t, 3H, J = 7.5 Hz, CH$_3$CH$_2$), 1.13 (d, J = 6.6 Hz, CH$_3$) ppm. $^{13}$C NMR (100 MHz, MeOD): $\delta$ 165.96, 160.65, 159.56, 157.32, 153.15, 137.63, 132.62, 131.50, 114.63, 89.92, 78.70, 75.67, 75.56, 55.61, 42.93, 20.31, 14.69 ppm. HRMS m/z calcd for C$_{22}$H$_{28}$N$_{10}$O$_4$ 497.2373 (M$^+$ +H), found 497.2378.
2-[1-(R,S)-Methyl-2-phenylethlamino]-5’-(2-ethyl-2H-tetrazol-5-yl)adenosine (1).  
1H NMR (400 MHz, MeOD): δ 8.10 (s, 1H, NCH=N), 7.26 (s, 5H, C6H5), 6.13 (d, J = 4.5 Hz, 1H, CH=O), 5.32 (d, J = 4.5 Hz, 1H, NCC=O), 4.75 (m, 1H, CHO), 4.70 (m, 1H, CHO), 4.69 (q, 2H, J = 7.5 Hz CH2CH3), 4.29 (m, 1H, CH), 2.98 (dd, J = 13.5 Hz, J’ = 5.7 Hz, 1H, CH2), 2.71 (dd, J = 13.2 Hz, J’ = 7.2 Hz, 1H, CH2), 1.60 (t, 3H, J = 7.5 Hz, CH2CH3), 1.15 (d, J = 6.6 Hz, CH3) ppm. HRMS m/z calcd for C21H25N10O3 467.2265 (M+ +H) found 467.2265.

2-[1-(R,S)-Methyl-2-(4-fluorophenyl)ethlamino]-5’-(2-ethyl-2H-tetrazol-5-yl)adenosine (2). HRMS m/z calcd for C21H25F3N10O3 535.2173 (M+ +H) found 535.2192 (Chart S1).

2-[1-(R,S)-Methyl-2-(4-chlorophenyl)ethlamino]-5’-(2-ethyl-2H-tetrazol-5-yl)adenosine (3). 1H NMR (400 MHz, MeOD): δ 8.10 (s, 1H, NCH=N), 7.26 (d, J = 8.7 Hz, 2H, C6H4), 7.20 (d, J = 9 Hz, 2H, C6H4), 6.13 (d, J = 4.5 Hz, 1H, CHO), 5.32 (d, J = 4.5 Hz, 1H, NCC=O), 4.72 (m, 1H, CHO), 4.70 (m, 1H, CHO), 4.69 (q, 2H, J = 7.5 Hz CH2CH3), 4.23 (m, 1H, CH), 2.89 (dd, J = 13.5 Hz, J’ = 5.7 Hz, 1H, CH2), 2.72 (dd, J = 13.2 Hz, J’ = 7.2 Hz, 1H, CH2), 1.60 (t, 3H, J = 7.5 Hz, CH2CH3), 1.13 (d, J = 6.6 Hz, CH3) ppm. HRMS m/z calcd for C22H27ClN10O3 543.1216 (M+ -H) found 543.1236.

2-[1-(R,S)-Methyl-2-(4-bromophenyl)ethlamino]-5’-(2-ethyl-2H-tetrazol-5-yl)adenosine (4). 1H NMR (500 MHz, MeOD): δ 8.10 (s, 1H, NCH=N), 7.40 (d, J = 7 Hz, 2H, C6H4), 7.20 (d, J = 8.5 Hz, 2H, C6H4), 6.13 (d, J = 4.5 Hz, 1H, CHO), 5.32 (d, J = 4.5 Hz, 1H, NCC=O), 4.74 (m, 1H, CHO), 4.72 (m, 1H, CHO), 4.70 (q, 2H, J = 7.5 Hz CH2CH3), 4.28 (m, 1H, CH), 2.94 (dd, J = 13.5 Hz, J’ = 5.7 Hz, 1H, CH2), 2.70 (dd, J = 13.2 Hz, J’ = 7.2 Hz, 1H, CH2), 1.60 (t, 3H, J = 7.5 Hz, CH2CH3), 1.15 (d, J = 6.6 Hz, CH3) ppm. HRMS m/z calcd for C22H27BrN10O3 543.1216 (M+ -H) found 543.1236.

2-[1-(R,S)-Methyl-2-(4-trifluoromethylphenyl)ethlamino]-5’-(2-ethyl-2H-tetrazol-5-yl)adenosine (5). HRMS m/z calcd for C22H27F3N10O3 535.2141 (M+ +H) found 535.2154 (Chart S1).

2-[1-(R,S)-Methyl-2-(4-methoxyphenyl)ethlamino]-5’-(2-ethyl-2H-tetrazol-5-yl)adenosine (R,S)-6. The NMR data were identical to the corresponding compound (R)-6. HRMS m/z calcd for C22H28N10O4 497.2373 (M+ +H) found 497.2379.

2-[1-(S)-Methyl-2-(4-methoxyphenyl)ethlamino]-5’-(2-ethyl-2H-tetrazol-5-yl)adenosine (S)-6. The NMR data were identical to the corresponding compound (R)-6. HRMS m/z calcd for C22H28N10O4 497.2373 (M+ +H) found 497.2357.

2-[1-(R,S)-Methyl-2-(3-methoxyphenyl)ethlamino]-5’-(2-ethyl-2H-tetrazol-5-yl)adenosine (R,S)-7. 1H NMR (400 MHz, MeOD): δ 8.10 (s, 1H, NCH=N), 7.21 (t, J = 6.2 Hz, 1H, C6H4), 6.75 (m, 3H, C6H4), 6.15 (d, J = 4.5 Hz, 1H, CHO), 5.30 (d, J = 4.5 Hz, 1H, NCC=O), 4.72 (m, 1H, CHO), 4.71 (m, 1H, CHO), 4.69 (q, 2H, J = 7.5 Hz CH2CH3), 4.25 (m, 1H, CH), 3.75 (s, 3H, OCH3), 2.89 (dd, J = 13.5 Hz, J’ = 5.7 Hz, 1H, CH2), 2.64 (dd, J = 13.2 Hz, J’ = 7.2 Hz, 1H, CH2), 1.61 (t, 3H, J = 7.5 Hz, CH2CH3), 1.15 (d, J = 6.6 Hz, CH3) ppm. HRMS m/z calcd for C22H28N10O4 497.2373 (M+ +H) found 497.2364.
2-Chloro-5'-(2-ethyl-2H-tetrazol-5-yl)adenosine (8). This compound was prepared as previously described.\(^1\) \(^1\)H-NMR (300 MHz, DMSO), \(\delta\): 8.40 (s, 1H, NCH\(_{\text{N}}\)\(_\text{N}\)), 7.81 (bs, 2H, NH\(_2\)), 6.04 (d, J=5.4 Hz, 1H, CHO), 5.78 (dd, J=6.9 Hz, J'=6 Hz, 1H, CH\(_{\text{O}}\)), 5.21 (d, J=4.2 Hz, 1H, CH\(_{\text{C}}\)N\(_\text{N}\)), 4.79 (q, J=5.1 Hz, 1H, OH), 4.72 (q, J=7.5 Hz, 2H, CH\(_2\)CH\(_3\)), 4.57 (q, J=4.2 Hz, 1H, OH), 1.29 (t, J=7.5 Hz, 3H, CH\(_2\)C\(_{\text{H}}\)\(_3\)), ppm.

\(^{13}\)C-NMR (50 MHz, d\(_6\)-DMSO), \(\delta\): 164.31, 156.99, 153.44, 150.75, 139.65, 118.17, 87.79, 77.40, 73.97, 73.69, 48.41, 48.41, 14.25 ppm.

2-Dimethylamino 5'-(2-ethyl-2H-tetrazol-5-yl)adenosine (9). A mixture of compound 8 (50 mg, 0.136 mmol), 1-phenylpropan-2-amine (12a) (40 mg, 0.299 mmol), \(i\)-Pr\(_2\)NEt (240 µL, 1.36 mmol), DMF (1.3 mL) and NaI as catalyst was heated under Ar at 145ºC for 70 h. The mixture was treated as above and the residue was purified through an Isolute C-18 cartridge followed by semipreparative HPLC using mixtures of MeOH:H\(_2\)O (50-95% MeOH) to give compound 9 (21 mg, 41% yield). \(^1\)H NMR (500 MHz, MeOD): \(\delta\): 8.10 (s, 1H, NCH\(_{\text{N}}\)\(_\text{N}\)), 6.13 (d, J = 4.5 Hz, 1H, CH\(_{\text{O}}\)), 5.29 (d, J = 5 Hz, 1H, CH\(_{\text{O}}\)), 4.93 (t, J = 5 Hz, 1H, CH\(_3\)), 4.79 (t, J = 4.5 Hz, 1H, CH\(_{\text{O}}\)), 4.72 (dd, J = 7 Hz, J'= 14.5 Hz, 2H, CH\(_2\)CH\(_3\)), 3.14 (S, 6H, CH\(_3\)), 1.62 (t, J = 7.5 Hz, 3H, CH\(_3\)), ppm. HRMS m/z calcd for C\(_{14}\)H\(_{19}\)N\(_1\)O\(_3\) 375.1642 (M\(^+\)-H) found 375.1635.

2-(1-Methyl-2-phenylethylamino)adenosine (10). A mixture of compound 13 (25 mg, 0.083 mmol), 1-phenylpropan-2-amine (12a) (25 mg, 0.183 mmol), Et\(_3\)N (190 µL, 1.33 mmol), DMSO (50 µL) and NaI as catalyst was heated under Ar at 145ºC for 48 h. The mixture was cooled to room temperature, diluted with AcOEt (5 mL), and the volatile materials were removed under vacuum. The residue was diluted with CH\(_2\)Cl\(_2\) (5 mL), washed with brine (3 x 5 mL) and the organic phase was dried (MgSO\(_4\)). After filtering, the solvent was stripped off. The residue was purified through an Isolute column C18 cartridge, followed by semipreparative HPLC using an isocratic mixture of H\(_2\)O:MeOH (40:60) to afford compound 10 (11.9 mg, 36%). \(^1\)H NMR (400 MHz, d\(_6\)-DMSO): \(\delta\): 7.90 (s, 1H, NCH\(_{\text{N}}\)\(_\text{N}\)), 7.17 (s, 1H, NH), 6.72 (s, 2H, NH\(_2\)), 6.04 (s, 1H, CHO), 5.73 (d, J = 5.6 Hz, 1H, CHO), 5.37 (m, 1H, CHO), 5.12 (s, 2H, OH), 4.57 (m, 1H, CHO), 4.12 (s, 2H, CH\(_3\)), 3.88 (s, 1H, OH), 3.65 (m, 2H, CH\(_2\)), 2.90 (m, 1H, CH), 106 (d, J = 5.2 Hz, CH\(_3\)) ppm. HRMS m/z calcd for C\(_{19}\)H\(_{24}\)N\(_6\)O\(_4\) 399.1781 (M\(^+\)-H) found 399.1766.

Radioligand binding assays

Radioligand binding competition assays were performed in vitro using A\(_1\), A\(_2\)A, A\(_2\)B and A\(_3\) human receptors expressed in transfected CHO (A\(_1\)), HeLa (A\(_2\)A and A\(_3\)) and HEK-293 (A\(_2\)B) cells. The experimental conditions used are summarized in Table 1S. In each instance aliquots of membranes (15 µg for A\(_1\), 8 µg for A\(_2\)A, 40 µg for A\(_2\)B and 100 µg for A\(_3\)) in buffer A (see Table 1S) were incubated for the specified period at 25 ºC with the radioligand (2-35 nM) and 6 different concentrations (ranging from 0.1 nM to 1 µM) of the test molecule or standard in a final volume of 200 µl. The binding reaction was stopped by rapid filtration in a multiscreen manifold system (Millipore Ibérica, Madrid, Spain). Unbound radioligand was removed by washing 4x with 250 µl of ice-cold buffer B for A\(_1\), A\(_2\)A and A\(_2\)B receptors, and 6x 250 µl of ice-cold buffer B for A\(_3\) receptor (see Table 1S). Non-specific binding was determined using a 50 µM NECA solution for A\(_2\)A receptors and 10-1000 µM R-PIA solution for A\(_1\), A\(_2\)A and A\(_3\) receptors. Radioactivity retained on filters was determined by liquid scintillation counting using Universol (ICN
Elemental Composition Report

Single Mass Analysis
Tolerance = 5.0 PPM  /  DBE: min = -1.5, max = 50.0
Element prediction: Off
Number of isotopic peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions
43 formula(e) evaluated with 2 results within limits (up to 50 best isotopic matches for each mass)
Elements Used:
AR136c
AR136c 29 (0.297) Cm (27:33)

Elemental Composition Report

Single Mass Analysis
Tolerance = 10.0 PPM  /  DBE: min = -1.5, max = 50.0
Element prediction: Off
Number of isotopic peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions
53 formula(e) evaluated with 2 results within limits (up to 50 best isotopic matches for each mass)
Elements Used:
C: 20-24  H: 20-30  N: 8-12  O: 0-3  F: 0-4
AR138
AR138 12 (0.187) Cm (12:13)

Chart S1
Biochemicals, Inc.). The binding affinities were determined using $[^3H]$-DPCPX (120 Ci/mmol; NEN-Perkin Elmer Life Sciences, Madrid, Spain) as the radioligand for A$_1$ and A$_{2B}$, $[^3H]$-ZM241385 (50 Ci/mmol; ARC-ITISA, Madrid, Spain) for A$_{2A}$ and $[^3H]$-NECA (18.6 Ci/mmol; NEN-Perkin Elmer Life Sciences, Madrid, Spain) for A$_3$. The inhibition constant ($K_i$) of each compound was calculated by the expression $K_i = IC_{50}/ (1+(C/K_D))$, where IC$_{50}$ is the concentration of compound that displaces the binding of radioligand by 50%, C is the free concentration of radioligand and $K_D$ is the apparent dissociation constant of each radioligand.

cAMP assays

cAMP assays were performed on transfected adenosine receptors using a cAMP enzyme immunoassay kit (GE-Healthcare). Because A$_{2A}$ are Gs-coupled receptors, competition curves were performed based on the NECA-induced cAMP accumulation. In turn, A$_3$ are Gi/o-coupled receptors and, therefore, competition curves were obtained over the NECA-induced inhibition of the cAMP accumulation produced by forskolin.

Human A$_{2A}$ receptors

CHO-A$_{2A}$ cells were seeded (10000 cells/well) in 96-well culture plates and incubated at 37°C in an atmosphere with 5% CO$_2$ in Dulbecco’s modified Eagle’s medium nutrient mixture F-12 (DMEM F-12), containing 10% fetal calf serum (FCS) and 1% L-glutamine. Cells were washed 3x with 200 µl of assay medium (DMEM-F12 and 25 mM HEPES pH=7.4), and pre-incubated with the assay medium containing 30 µM Rolipram and the test compounds at 37°C for 15 min. NECA was incubated for 15 min at 37°C (total incubation time 30 min). The reaction was stopped with the lysis buffer supplied with the kit and detection of intracellular cAMP was performed by the enzyme immunoassay at 450 nm in an M1000 Pro Reader (Tecan). Data were fitted by non-linear regression using GraphPad Prism v2.01 (GraphPad Software).

Human A$_3$ receptors

CHO-A$_3$ cells were seeded (20000 cells/well) in 96-well culture plates and incubated at 37°C in an atmosphere with 5% CO$_2$ Dulbecco’s Medium Nutrient F-12 (DMEM F-12), containing 10% FCS and 1% L-glutamine, as above. Cells were washed and pre-incubated with the test compounds as cited for A$_{2A}$ receptors. NECA was incubated also at 37°C for 15 min and forskolin (10 µM) was also incubated for 3 min (total incubation time 33 min). The reaction was stopped with the lysis buffer supplied with the kit and the enzyme immunoassay performed as cited above. Data were also fitted by non-linear regression using GraphPad Prism v2.01.
Table 1S  Experimental conditions used for radioligand binding assays using A1, A2A, A2B, and A3 human receptors.

<table>
<thead>
<tr>
<th></th>
<th>A1</th>
<th>A2A</th>
<th>A2B</th>
<th>A3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cell line</strong></td>
<td>CHO-A1</td>
<td>HeLa-A2A</td>
<td>HEK-A2B</td>
<td>HeLa-A3</td>
</tr>
<tr>
<td><strong>Buffer A</strong></td>
<td>20 mM Hepes, 100 mM NaCl, 10 mM MgCl2, 2 units/ml adenosine deaminase (pH=7.4)</td>
<td>50 mM Tris-HCl, 1mM EDTA, 10 mM MgCl2, 2 units/ml adenosine deaminase (pH=7.4)</td>
<td>50 mM Tris-HCl, 1mM EDTA, 5 mM MgCl2, 2 units/ml adenosine deaminase (pH=6.5)</td>
<td>50 mM Tris-HCl, 1mM EDTA, 2 units/ml adenosine deaminase (pH=7.4)</td>
</tr>
<tr>
<td><strong>Buffer B</strong></td>
<td>20 mM Hepes, 100 mM NaCl, 10 mM MgCl2, (pH=7.4)</td>
<td>50 mM Tris-HCl, 1mM EDTA, 10 mM MgCl2, (pH=7.4)</td>
<td>50 mM Tris-HCl, 1mM EDTA, 5 mM MgCl2, (pH=6.5)</td>
<td>50 mM Tris-HCl, (pH=7.4)</td>
</tr>
<tr>
<td><strong>Plate</strong></td>
<td>GF/C</td>
<td>GF/C</td>
<td>GF/C</td>
<td>GF/B</td>
</tr>
<tr>
<td><strong>Non-specific binding</strong></td>
<td>10 µM (R)-PIA</td>
<td>50 µM NECA</td>
<td>1000 µM (R)-PIA</td>
<td>100 µM (R)-PIA</td>
</tr>
<tr>
<td><strong>Incubation</strong></td>
<td>25°C/60 min</td>
<td>25°C/30 min</td>
<td>25°C/30 min</td>
<td>25°C/180 min</td>
</tr>
</tbody>
</table>

**Molecular modelling**

The three available agonist-bound crystal structures of the A2AR were initially considered, i.e. receptors co-crystallized with adenosine (PDB code 2YDO), 5′-N-ethylcarboxamidoadenosine (NECA, PDB code 2YDV) and UK432097 (a derivative of NECA with bulky N6 and C2 substitutions, PDB code 3QAK). A first docking exploration with the agonist series reported1 (Fig. S1), revealed a more consistent binding mode when using the NECA-bound complex, probably due to the more enclosed conformation of the extracellular loops compared to the UK432097-bound structure.

The A2AR-NECA complex was equilibrated using the molecular dynamics (MD) protocol implemented in GPCR-ModSim (http://gpcr-modsim.org),2 which is here explained in brief. First, missing protein atoms and residue protonation states were modelled for the A2AR structure with tools from the Schrödinger software suite.3 The coordinates of the crystallographic receptor, ligand and water molecules observed in the binding cavity were then prepared to be simulated in GROMACS v4.0.5.4 The complex was embedded in a pre-equilibrated hydrated POPC (1-palmitoyl-2-oleoylphosphatidylcholine) lipid bilayer, following the appropriate orientation adopted by GPCRs in the membrane. The system was then neutralized with counterions, and arranged in a simulation box with a hexagonal prism-shaped geometry comprising ~50,000 atoms (74% solvent molecules, 15% lipids, and 11% protein and ligand atoms). The OPLS all-atom (OPLS-AA) force field5 was used for the protein, the corresponding parameters were generated for the ligand with Macromodel,3 and the
double-pairlist half-epsilon method was followed to make the Berger united-atom parameters used for the POPC lipids compatible with the rest of the system. After a steepest-descent energy minimization, 5 ns of partially-restrained MD simulation were performed with GROMACS4.0.5. This equilibration protocol consists of a first stage of 2.5 ns where positional restraints on the heavy atoms of the protein, ligand, and crystallographic waters are gradually reduced, followed by 2.5 ns with only weak positional restraints on the protein Cα atoms. Very small rearrangements were observed for NECA and binding site residues, while water molecules further optimized an internal-ligand and receptor-ligand interaction networks (Fig. S2).

Compounds described in the text were docked to the MD-equilibrated A2A AR receptor, including two binding site water molecules, with the protein-ligand docking program GOLD version 4.1. The 3D conformers of each ligand, including their possible R and S enantiomers, were built and optimized using the Maestro graphical interface and the LigPrep utility from the Schrödinger suite. Twenty genetic algorithm (GA) runs were performed with GOLD. High accuracy search parameters were used, allowing full flexibility of the ligand, e.g. flipping of amide bonds. A search sphere with a radius of 15 Å was centered on the side chain (CD1) of Ile274, which comprises the agonist binding site observed in active-like structures of the A2A AR. Ligand conformations from docking experiments were selected according to a combination of their predicted binding energies with the ChemScore scoring function, and the population (convergence) of the solutions according to an RMSD clustering criteria of 1 Å. Finally, the ligands were energy-minimized in the binding site with Macromodel, with the crystallographic water and receptor coordinates held rigid.
Fig. S1. Predicted binding mode for compound 5 in Bosch et al.¹

Fig. S2. MD equilibration of the A₂AR-NECA crystallographic coordinates. Binding site residues and NECA are represented in lines and sticks for the pre- and post-MD coordinates, respectively. The crystallographic waters included in the simulations are shown in spheres, while their MD-refined coordinates are represented in sticks.
**Abbreviations**

UPLC = ultra-performance liquid chromatography; TOF = time of flight; i-Pr$_2$NEt = diisopropylethylamine; DBU = 1,8-diazabicyclo[5,4,0]undec-7-ene; DMSO = dimethyl sulfoxide; DMF = N,N-dimethyl formamide; cAMP = 3’-5’ cyclic adenosine monophosphate; NECA = 5’-(N-ethylcarboxamido)adenosine; DPCPX = 1,3-dipropyl-8-cyclopentylxanthine; ZM241385 = (7-amino-2-(2-furyl)-5-[2-(4-hydroxyphenyl)ethyl]amino-[1,2,4]-triazolo[1,5-a][1,3,5]triazine; GPCR = G-protein coupled receptor.

**REFERENCES**